Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 14/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30944813 | 0.93 | GPR119 (0.40) | GPR119HPGDRECQLEPHX1 | |
| SCHEMBL30944812 | 0.93 | GPR119 (0.40) | GPR119HPGDRECQLEPHX1 | |
| SCHEMBL16757588 | 0.89 | PKM (0.40) | GPR119HPGDRECQLEPHX1MEN1 | |
| SCHEMBL30886193 | 0.89 | PKM (0.40) | GPR119HPGDRECQLEPHX1MEN1 | |
| SCHEMBL28774247 | 0.88 | GPR119 (0.36) | GPR119HPGDRECQLEPHX1MEN1 | |
| SCHEMBL28504795 | 0.85 | GPR119 (0.34) | GPR119HPGDMEN1KMT2A | |
| SCHEMBL28504794 | 0.85 | GPR119 (0.34) | GPR119HPGDMEN1KMT2A | |
| SCHEMBL17322786 | 0.83 | KMT2A (0.39) | GPR119MEN1KMT2A | |
| SCHEMBL30944814 | 0.79 | GPR119 (0.38) | GPR119HPGD | |
| SCHEMBL21836125 | 0.78 | GPR119 (0.35) | GPR119HPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11857637-B2 | Anti-CD25 antibody-maytansine conjugates and methods of use thereof | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2024-01-02 | — | — | US | disclosed |
| US-20150352225-A1 | Anti-Her2 Antibody-Maytansine Conjugates and Methods of Use Thereof | R.P. SCHERER TECHNOLOGIES, INC. | 2015-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150352225-A1 | Anti-Her2 Antibody-Maytansine Conjugates and Methods of Use Thereof | ERBB2, EGFR, ERBB3 | GPR119 1319/4885HPGD 1512/4885RECQL 4312/4885 |
| US-11857637-B2 | Anti-CD25 antibody-maytansine conjugates and methods of use thereof | IL2RA, IL2, CD2 | GPR119 1136/4885HPGD 381/4885RECQL 4506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.